课题基金 / 基金详情

ACTG--PHARMACOKINETIC AND TOLERANCE STUDY OF ORAL GANCICLOVIR

ACTG--PHARMACOKINETIC AND TOLERANCE STUDY OF ORAL GANCICLOVIR
ACTG--口服更昔洛韦的药代动力学和耐受性研究
批准号：
6245169
负责人：
Ram Yogev
金额：
$1.2万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-07-15 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245169
关键词：
AIDS therapy HIV infections Herpesviridae disease adolescence (12-20) child (0-11) clinical research clinical trial phase I cytomegalovirus dosage drug screening /evaluation drug tolerance ganciclovir human subject human therapy evaluation longitudinal human study oral administration pediatric AIDS pharmacokinetics

项目摘要

项目成果

Ram Yogev的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 226 is a phase I, open-label, dose-escalating trial of oral Ganciclovir in HIV-infected children aged 2 mths-20 yrs with asymptomatic cytomegalovirus (CMV) and low CD4 cell counts or with quiescent CMV disease. The purposes of this study are to evaluate the pharmacokinetics, long-term safety and tolerance, and maximum tolerated dose of oral Ganciclovir in HIV-infected patients, and to evaluate the effect of oral Ganciclovir on the virologic parameters of CMV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
海外基金